Direct answer: There are at least two separate companies that match the name "IMMUNIO/Immunio" (and a third similarly named “Immuno Technologies”) in public business listings — one is a Montreal-based cybersecurity / IT services firm doing business as IMMUNIO, and another (Immuno Technologies / Immuno Technologies, Inc.) is a U.S. preclinical biotech company focused on diagnostics and vaccines for spirochetal diseases; available public records do not show a single dominant, widely-known company called simply “IMMUNIO” that unambiguously covers both profiles.[3][2]
High‑Level Overview
- IMMUNIO (cybersecurity / IT services): Registered listings describe a Montreal, Quebec–based IT services, consulting and cybersecurity company with several million dollars in revenue; it provides security and IT managed services to enterprise clients (public business directory summaries).[3]
- Immuno Technologies / Immuno Technologies, Inc. (biotech): A Memphis, Tennessee–based preclinical research company focused on vaccines, monoclonal antibodies and diagnostic assays for Lyme disease, leptospirosis and other spirochetal infections; it pursues non‑dilutive SBIR/STTR funding and seeks strategic licensing or alliances for commercialization of IP.[2][1]
For an investment firm (if you meant IMMUNIO as a VC / investor): I could not find authoritative public records describing an investment firm named IMMUNIO; please confirm if you meant a different entity or provide a link so I can pull firm-specific details (mission, philosophy, sectors, ecosystem impact).
For a portfolio company (if you meant IMMUNIO the cybersecurity firm):
- What product it builds: Public summaries list IT services and cybersecurity offerings but do not include a detailed product sheet in searchable directories.[3]
- Who it serves: Enterprise and mid‑market clients needing IT/security services per directory profile.[3]
- What problem it solves: IT operations, managed security and consulting to reduce cyber risk and support infrastructure (inferred from industry classification).[3]
- Growth momentum: Business listings report estimated revenue (~$8.2M in one directory) but I did not find recent funding announcements, growth metrics, or press coverage to document momentum or ARR trends[3]. (This is a gap — see “Limitations” below.)
For a biotech portfolio company (Immuno Technologies, Inc.):
- What product it builds: Preclinical vaccine candidates, monoclonal antibody therapies and immunodiagnostic assays targeting spirochetal diseases such as Lyme disease and leptospirosis[2][1].
- Who it serves: Researchers, public health stakeholders, veterinarians and ultimately patients and commercial partners that would license or commercialize products[2].
- What problem it solves: Improved prevention (vaccines) and diagnostics for under‑served spirochetal infections that currently lack highly effective commercial products[2].
- Growth momentum: The company relies on SBIR grants since 2014 and positions itself for strategic alliances or licensing when IP is mature; public sources show ongoing preclinical focus but no public venture financing or commercial revenues disclosed[2][1].
Origin Story
- IMMUNIO (cyber/IT): Public directories do not include founding year, founder names or detailed origin story for the Montreal IMMUNIO listing; available summaries focus on industry classification and revenue estimates[3].
- Immuno Technologies, Inc. (biotech): The company profile indicates a Memphis, TN base and a mission focused on preclinical research for vaccines and diagnostics for spirochetal diseases; it has pursued SBIR funding since at least 2014 and describes a commercialization strategy based on licensing IP or spinning out product companies, but public pages do not list founder biographies on the landing page I found[2][1].
Core Differentiators
- For the Montreal IMMUNIO (cyber/IT) — based on directory data (limited):
- Market focus: IT services + cybersecurity combined under one provider (value for customers seeking bundled services).[3]
- SME to enterprise operational scope: Directory indicates mid‑sized revenue suggesting scale to serve enterprise customers[3].
- (No verified public claims about unique tech, product differentiators or community ecosystem were found; additional primary sources needed.)
- For Immuno Technologies, Inc. (biotech):
- Research focus: Specialized in *spirochetal* diseases (narrow domain expertise) rather than broad infectious disease R&D[2].
- SBIR-backed pathway: Uses non‑dilutive government funding to de‑risk early preclinical work and advance proof‑of‑principle / pre‑IND studies[2].
- IP/licensing commercialization model: Intends to license or spin out assets once IP is secured to partners able to commercialize biologics[2].
Role in the Broader Tech / Health Landscape
- Cyber/IT IMMUNIO: Fits the ongoing trend of consolidation between managed IT services and cybersecurity as enterprises seek vendors that handle both operations and security; market forces include rising cyber risk, regulatory pressure and demand for managed security[3]. (This is an inference based on the company’s industry classification; no direct public commentary from the company was found.)
- Immuno Technologies, Inc.: Rides the broader biotech trend of focused, small teams using government funding (SBIR) to advance preclinical assets in niche or neglected disease areas, then partnering with larger biopharma for costly late‑stage development and commercialization; timing matters because Lyme and related infections are receiving more attention for diagnostics and vaccines, and smaller players can move quickly in preclinical spaces[2][1].
Quick Take & Future Outlook
- For the Montreal IMMUNIO (cyber/IT): If you’re evaluating them as a vendor or investment target, primary diligence is needed: request product documentation, customer references, leadership bios and recent financials; the company’s public footprint in directories is limited so direct engagement is required to assess growth prospects and differentiation[3].
- For Immuno Technologies, Inc. (biotech): Expect continued SBIR‑funded preclinical work and an emphasis on securing IP and strategic partners; the next material milestones would be IND‑enabling studies, licensing deals or spin‑out formation—events that would materially change valuation and visibility[2][1].
Limitations and next steps
- The available public records are sparse and fragmented: one directory entry for a Montreal IT company named IMMUNIO provides a revenue estimate but no detailed product, team, or press; Immuno Technologies has a fuller company site but limited public disclosure of founders and specific pipelines beyond thematic descriptions[3][2][1].
- If you want a deeper, verified profile, I can:
- Search corporate registries (Quebec / Canada) for IMMUNIO’s incorporation documents and leadership; or
- Pull FDA/clinical registry, patent, grant (SBIR) and scientific publication records for Immuno Technologies to detail programs, founders, and milestone timelines.
Which of these companies did you mean (the Montreal cybersecurity IMMUNIO, U.S. Immuno Technologies biotech, or another entity)? I’ll run targeted searches and assemble a more detailed, cited profile once you confirm.
